secwatch / observer
8-K filed January 16, 2026, 6:59 PM ET ticker COR CIK 0001140859
debt confidence high sentiment neutral materiality 0.75

Cencora, Inc. (COR): debt financing — Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced

Cencora, Inc.

item 1.01item 2.03item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Cencora, Inc. amended revolving credit of by $1.0 billion to $5.5 billion with JPMorgan Chase Bank, N.A., as administrative agent.

Instrument
revolving credit
Principal
by $1.0 billion to $5.5 billion
Counterparty
JPMorgan Chase Bank, N.A., as administrative agent
Event
amendment
Exact text from the filing
The Amendment increased the aggregate amount of the commitments under the Revolving Credit Agreement by $1.0 billion to $5.5 billion.
View on SEC.gov
Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Cencora, Inc. incurred term loan of $1.5 billion with JPMorgan Chase Bank, N.A., as administrative agent at a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app maturing Tranche One Loans mature two years from the date on which they are drawn. Tranche Two Loans mature three years from the date on which they are drawn.

Instrument
term loan
Principal
$1.5 billion
Counterparty
JPMorgan Chase Bank, N.A., as administrative agent
Rate
a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app
Maturity
Tranche One Loans mature two years from the date on which they are drawn. Tranche Two Loans mature three years from the date on which they are drawn
Event
incurrence
Exact text from the filing
On January 12, 2026, the Company entered into a Term Credit Agreement (the "Term Credit Agreement"), among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, in connection with the previously announced proposed acquisition (the "Acquisition") of the majority of the outstanding equity interests that the Company does not currently own in OneOncology. The Term Credit Agreement provides for a senior unsecured term loan facility of $1.5 billion consisting of two tranches: (a) $500 million ("Tranche One Loans") and (b) $1.0 billion ("Tranche Two Loans" and together with Tranche One Loans, the "Term Loans").
View on SEC.gov
Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Cencora, Inc. incurred term loan of $3.0 billion with Citibank, N.A., as administrative agent at a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app maturing The 364-Day Term Loan matures 364 days from the date on which it is drawn.

Instrument
term loan
Principal
$3.0 billion
Counterparty
Citibank, N.A., as administrative agent
Rate
a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app
Maturity
The 364-Day Term Loan matures 364 days from the date on which it is drawn
Event
incurrence
Exact text from the filing
On January 12, 2026, the Company entered into a Credit Agreement (the "364-Day Term Credit Agreement"), among the Company, the lenders party thereto and Citibank, N.A., as administrative agent, in connection with the Acquisition. The 364-Day Term Credit Agreement provides for a senior unsecured term loan facility of $3.0 billion (the "364-Day Term Loan").
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cencora, Inc. amended Incremental Facility and Amendment Agreement with JPMorgan Chase Bank, N.A. valued at $1.0 billion (effective 2026-01-12).

Action
amendment
Agreement
credit facility
Counterparty
JPMorgan Chase Bank, N.A.
Value
$1.0 billion
Effective
2026-01-12
Exact text from the filing
On January 12, 2026, Cencora, Inc. (the “Company”) entered into an Incremental Facility and Amendment Agreement (the “Amendment”) to that certain Amended and Restated Credit Agreement (as amended by the Amendment, the “Revolving Credit Agreement”), dated as of June 4, 2025, among the Company, the borrowing subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cencora, Inc. entered into 364-Day Term Credit Agreement with Citibank, N.A. valued at $3.0 billion (effective 2026-01-12).

Action
entry
Agreement
credit facility
Counterparty
Citibank, N.A.
Value
$3.0 billion
Effective
2026-01-12
Exact text from the filing
On January 12, 2026, the Company entered into a Credit Agreement (the “364-Day Term Credit Agreement”), among the Company, the lenders party thereto and Citibank, N.A., as administrative agent, in connection with the Acquisition.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cencora, Inc. entered into Term Credit Agreement with JPMorgan Chase Bank, N.A. valued at $1.5 billion (effective 2026-01-12).

Action
entry
Agreement
credit facility
Counterparty
JPMorgan Chase Bank, N.A.
Value
$1.5 billion
Effective
2026-01-12
Exact text from the filing
On January 12, 2026, the Company entered into a Term Credit Agreement (the “Term Credit Agreement”), among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, in connection with the previously announced proposed acquisition (the “Acquisition”) of the majority of the outstanding equity interests that the Company does not currently own in OneOncology.
View on SEC.gov

114 debt financings filed in the last 30 days. Browse all debt financings →

Cencora, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-004524
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.